BioCardia CEO Peter Altman buys $5,022 in company stock

BioCardia CEO and President Peter Altman bolstered his stake in the company by purchasing 5,400 shares on August 17, 2026, for a total of $5,022. The acquisition was made at prices between $0.92 and $0.97 per share, with a weighted average price of $0.93 per share. Despite a 50% decline over the past year, the stock is trading close to its 52-week low of $0.75. According to InvestingPro analysis, BioCardia Inc. appears undervalued at the moment, with a Fair Value pointing to potential upside.

Following the purchase, Altman directly owns 381,115 shares of BioCardia common stock, representing 13.14% of the company's outstanding shares. Investors can obtain a more comprehensive view of BioCardia's financial health by accessing the Pro Research Report, which covers the company alongside 1,400+ other US equities.

Recently, BioCardia reported a smaller-than-expected loss for the second quarter of 2026, with an adjusted earnings per share (EPS) loss of $0.13, outperforming the $0.18 loss expected by analysts—a 27.78% surprise. This positive earnings news comes alongside significant regulatory progress, with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approving a Shonin submission for BioCardia's CardiAMP cell therapy.

Furthermore, the U.S. Food and Drug Administration (FDA) staff suggested that the CardiAMP Heart Failure II trial could support pre-market approval, bolstering the company's regulatory outlook in the United States.

BioCardia holds a cash reserve of $5.4 million at the end of the quarter, ensuring financial resilience into 2027. The company's net cash used in operations was $1.7 million for the quarter, slightly higher than the $1.6 million used in the same period from the previous year. Operating cash use for the first half of the year was $3.4 million, marginally up from the prior-year period. These developments underscore BioCardia's dedication to advancing its cell therapy and delivery platform.